2026-2034年全球合成大麻素市場規模、佔有率、趨勢和成長分析報告

預計合成大麻素市場將從 2025 年的 58.8 億美元成長到 2034 年的 336.3 億美元，2026 年至 2034 年的複合年成長率為 21.39%。

合成大麻素市場持續穩定成長，這主要得益於對新型治療應用的持續研究以及不斷變化的監管環境。與天然大麻素不同，合成大麻素旨在精準作用於大麻素受體，為疼痛管理、神經退化性疾病和腫瘤治療等領域提供了潛在的治療機會。然而，濫用、毒性和無序分銷等問題，以及嚴格的合規要求，也對市場發展產生影響。

製藥公司和研究機構正致力於開發安全、標準化的合成大麻素製劑。分子建模和生物技術的進步使得設計具有標靶治療效果且副作用最小的化合物成為可能。臨床試驗和專利申請數量的增加表明，基於大麻素的藥物商業化進展強勁。同時，嚴格的品管標準的實施確保了生產的一致性和安全性。

展望未來，已開發地區對大麻素療法的接受度不斷提高，以及法規結構的逐步改善，將對市場產生正面影響。合成大麻素替代品領域也將湧現出新的機遇，這些替代品能夠提供穩定的劑量和擴充性。隨著個人化和精準醫療的重要性日益凸顯，合成大麻素有望在醫療保健領域得到更廣泛的應用。生物技術創新者與製藥巨頭之間的策略合作將加速市場成熟。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球合成大麻素市場：依產品類型分類

• 市場分析、洞察與預測
• 高純度合成大麻素
• 超高純度合成大麻素

第5章：全球合成大麻素市場：依適應症分類

• 市場分析、洞察與預測
• 疼痛管理
• 噁心和嘔吐
• 神經系統疾病的管理
• 其他

第6章 全球合成大麻素市場：依分銷管道分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 網路藥房

第7章 全球合成大麻素市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Mylan NV
  • Alkem Labs
  • Noramco
  • Lygos Inc
  • Hyasynth Biologicals Inc
  • Renew Biopharma
  • CannBioRx Life Sciences
  • Ginkgo Bioworks
  • Zymergen Inc
  • Demetrix Inc

The Synthetic Cannabinoids Market size is expected to reach USD 33.63 Billion in 2034 from USD 5.88 Billion (2025) growing at a CAGR of 21.39% during 2026-2034.

The synthetic cannabinoids market is growing steadily, fueled by ongoing research into novel therapeutic applications and evolving regulatory landscapes. Unlike natural cannabinoids, synthetic variants are engineered to interact with cannabinoid receptors in precise ways, offering potential for treatments in pain management, neurodegenerative disorders, and oncology. However, the market is also shaped by strict compliance requirements due to concerns over misuse, toxicity, and unregulated distribution.

Pharmaceutical companies and research institutions are focusing on developing safe, standardized synthetic cannabinoid formulations. Advances in molecular modeling and biotechnology are enabling the design of compounds with targeted therapeutic effects while minimizing adverse reactions. Clinical trials and patent filings are increasing, indicating strong momentum toward commercialized cannabinoid-based medicines. Meanwhile, the adoption of stringent quality control standards is ensuring consistency and safety in production.

Looking forward, the market will benefit from increasing acceptance of cannabinoid therapies and progressive regulatory frameworks in developed regions. Opportunities will also emerge in synthetic alternatives to cannabis-derived products, offering consistent dosing and scalability. As personalized medicine and precision therapeutics gain prominence, synthetic cannabinoids are likely to find wider application across healthcare. Strategic partnerships between biotech innovators and pharmaceutical giants will accelerate market maturity.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product Type

• High-pure Synthetic Cannabinoid
• Ultra-pure Synthetic Cannabinoid

By Indication

• Pain Management
• Nausea/Vomiting
• Neurological Disorder Management
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Mylan NV, Alkem Labs, Noramco, Lygos Inc, Hyasynth Biologicals Inc, Renew Biopharma, CannBioRx Life Sciences, Ginkgo Bioworks, Zymergen Inc, Demetrix Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL SYNTHETIC CANNABINOIDS MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product Type
• 4.2. High-pure Synthetic Cannabinoid Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Ultra-pure Synthetic Cannabinoid Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL SYNTHETIC CANNABINOIDS MARKET: BY INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. Pain Management Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Nausea/Vomiting Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Neurological Disorder Management Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL SYNTHETIC CANNABINOIDS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL SYNTHETIC CANNABINOIDS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Product Type
  • 7.2.2 By Indication
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Product Type
  • 7.3.2 By Indication
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Product Type
  • 7.4.2 By Indication
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Product Type
  • 7.5.2 By Indication
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Product Type
  • 7.6.2 By Indication
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL SYNTHETIC CANNABINOIDS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Mylan N.V
  • 9.2.2 Alkem Labs
  • 9.2.3 Noramco
  • 9.2.4 Lygos Inc
  • 9.2.5 Hyasynth Biologicals Inc
  • 9.2.6 Renew Biopharma
  • 9.2.7 CannBioRx Life Sciences
  • 9.2.8 Ginkgo Bioworks
  • 9.2.9 Zymergen Inc
  • 9.2.10 Demetrix Inc